title: [Capsular polysaccharide antibodies after pneumococcal polysaccharide vaccination in patients with chronic respiratory disease].
abstract: We investigated the antibody response to a 23-valent pneumococcal polysaccharide vaccine (23PSV), in 151 patients (average age: 70 years old) with chronic respiratory disease. Serotype-specific IgG antibodies to 4 pneumococcal capsular polysaccharides (6B, 14, 19F, and 23F) were analyzed by ELISA before, and one month after, 23PSV vaccination in all patients. Patients showed a significant increase in specific IgG levels to Streptococcus pneumoniae after 23PSV vaccination (5.5 times-20.9 times). Even patients aged over 80, patients with respiratory failure, and patients receiving corticosteroid therapy developed a significant immunologic response to 23PSV. Local pain or induration occurred in 9.1-14.3% and fatigue or chills occurred in 0.7-6.5% of patients. All adverse reactions disappeared in 2 or 3 days and there was no severe adverse events. Further studies are needed to confirm the exact protective antibody level and to examine the decline of antibody level after vaccination.
authors.affiliation: Department of Respiratory, National Hospital Organization Tokyo Hospital.
authors.forename: Wakana
authors.initials: W
authors.lastname: Saito
authors.forename: Hideaki
authors.initials: H
authors.lastname: Nagai
authors.forename: Junko
authors.initials: J
authors.lastname: Suzuki
authors.forename: Kimihiko
authors.initials: K
authors.lastname: Masuda
authors.forename: Atsuhisa
authors.initials: A
authors.lastname: Tamura
authors.forename: Naohiro
authors.initials: N
authors.lastname: Nagayama
authors.forename: Shinobu
authors.initials: S
authors.lastname: Akagawa
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Kawabe
authors.forename: Kazuko
authors.initials: K
authors.lastname: Machida
authors.forename: Atsuyuki
authors.initials: A
authors.lastname: Kurashima
authors.forename: Hideki
authors.initials: H
authors.lastname: Yotsumoto
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Saito
authors.forename: Tomo
authors.initials: T
authors.lastname: Arai
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Okabe
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood*; D016667:Bacterial Capsules; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D022242:Pneumococcal Vaccines / Q000008:administration & dosage*; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D012120:Respiration Disorders / Q000276:immunology*; D013296:Streptococcus pneumoniae / Q000276:immunology*; D014611:Vaccination
chemical_list: D000907:Antibodies, Bacterial; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial